Skip to content
lsd.com
WithdrawnNot applicable

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

NCT01613820 · Massachusetts General Hospital

Closed to entry
Status
Not accepting participants
Not applicable
Phase
—
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. Scopolamine infusions produced also a significant improvement in depression that was sustained over time. We therefore plan to investigate the feasibility and efficacy of open-label repeated intravenous administration of ketamine and scopolamine combined in this population of severely depressed, treatment-resistant patients. The results from this study could lead to the development of new strategies for the treatment of patients with TRD.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Hamilton Depression Rating Scale - 28 items

    Measured over up to 4 months

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Outpatients with sever treatment-resistant depression * Currently depressed * Currently under regular psychiatric care * On an aggressive antidepressant regimen, stable for 4 weeks Exclusion Criteria: * No history of other major psychiatric illnesses, including bipolar disorder * No history of psychosis * No history of drug abuse * No major medical illness or unstable medical condition.

Where

1 study site

FacilityCityRegionCountry
Depression Clinical and Reseach Program - MGHBostonMassachusettsUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT01613820 on ClinicalTrials.gov →

Last updated in the registry 2018-02-19. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in

All 17 trials from Massachusetts General Hospital →